Expected outcomes and patients’ selection before chemoembolization—“Six-and-Twelve or Pre-TACE-Predict” scores may help clinicians: Real-life French cohorts results
暂无分享,去创建一个
R. Anty | J. Raoul | M. Bourlière | G. Pénaranda | J. Bronowicki | P. Chevallier | X. Adhoute | P. Castellani | O. Monnet | O. Bayle | H. Perrier | B. Pol | A. Tran | E. Larrey | M. Bourliere
[1] Yulei N. Wang,et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. , 2020, The New England journal of medicine.
[2] M. Huang,et al. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study , 2020, World journal of gastroenterology.
[3] M. Kudo,et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial , 2019, Gut.
[4] M. García-Fiñana,et al. Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response‐Based Approach , 2019, Hepatology.
[5] Hui Zhang,et al. Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. , 2019, Journal of hepatology.
[6] T. Labeur,et al. Reason of Discontinuation After Transarterial Chemoembolization Influences Survival in Patients with Hepatocellular Carcinoma , 2018, CardioVascular and Interventional Radiology.
[7] D. Stocken,et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. , 2017, The lancet. Gastroenterology & hepatology.
[8] P. Galle,et al. The treatment of intermediate stage tumours beyond TACE: From surgery to systemic therapy. , 2017, Journal of hepatology.
[9] J. Raoul,et al. NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization , 2017, European journal of gastroenterology & hepatology.
[10] R. Lencioni,et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data , 2016, Hepatology.
[11] R. Golfieri,et al. Refining prognosis after trans‐arterial chemo‐embolization for hepatocellular carcinoma , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[12] Riccardo Lencioni,et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. , 2016, Journal of hepatology.
[13] M. Kudo,et al. Subclassification of BCLC B Stage Hepatocellular Carcinoma and Treatment Strategies: Proposal of Modified Bolondi's Subclassification (Kinki Criteria) , 2015, Digestive Diseases.
[14] B. Sangro,et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Georg Heinze,et al. PSHREG: A SAS macro for proportional and nonproportional subdistribution hazards regression , 2015, Comput. Methods Programs Biomed..
[16] H. Heinzl,et al. How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. , 2014, Journal of hepatology.
[17] A. Burroughs,et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] V. Mazzaferro,et al. Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions , 2012, Seminars in Liver Disease.
[19] Tim Meyer,et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. , 2011, Journal of hepatology.
[20] O. Matsui,et al. Portal blood supply to locally progressed hepatocellular carcinoma after transcatheter arterial chemoembolization: Observation on CT during arterial portography , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.
[21] M. Carpenzano,et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5 cm) hepatocellular carcinomas , 2011, Hepatology.
[22] Riccardo Lencioni,et al. Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.
[23] Xueying Sun,et al. Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas , 2007, International journal of cancer.
[24] H. Honda,et al. Sequential hemodynamic change in hepatocellular carcinoma and dysplastic nodules: CT angiography and pathologic correlation. , 2002, AJR. American journal of roentgenology.
[25] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[26] M. Dumont,et al. European Association for the Study of the Liver , 1971 .
[27] J. Raoul,et al. Response to 'the flexible therapeutic approach to the BCLC B stage': Time for scoring systems? , 2017, Journal of hepatology.
[28] M. Monden,et al. Limitation of transcatheter arterial chemoembolization using iodized oil for small hepatocellular carcinoma. A study in resected cases , 1991, Cancer.